Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

16 Apr 2010

Exclusive licensing practices slows innovation in gene testing market

Exclusive licenses to gene patents, most of which are held by academic institutions and based on taxpayer-funded research, do more to block competition in the gene testing market than to spur the development of new technologies for gauging disease risk, say researchers at the Duke Institute for Genome Sciences & Policy (IGSP).

15 Apr 2010

FDA approves J&JPRD's PANCREAZE NDA

Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for PANCREAZE™ (pancrelipase) delayed-release capsules for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Exocrine pancreatic insufficiency is the inability to properly digest and absorb food due to a lack of enzymes made by the pancreas that are important in the digestion of fats, proteins, and sugars.

15 Apr 2010

Stem cell scientists receive stimulus grants to study lung and blood disorders

Stem cell scientists at The University of Texas Health Science Center at Houston (UTHealth) were awarded stimulus grants totaling almost $2 million to research experimental treatments for blood disorders and inherited lung diseases affecting children.

13 Apr 2010

Pancreaze Delayed Release Capsules receive FDA approval

The U.S. Food and Drug Administration today approved Pancreaze Delayed Release Capsules, a pancreatic enzyme product. It is the third such product to receive FDA approval.

13 Apr 2010

Latest advancement in the development of lab tests for bipolar disorder

Genetic testing may rise to a new level with the findings of Indiana University School of Medicine researchers whose "prototype" for laboratory testing for bipolar disorder appears today in the online edition of the American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.

9 Apr 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

In a clinical trial known as PROVE 3 published in this week's New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response (SVR) in patients with genotype 1 hepatitis C virus (HCV) infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.

8 Apr 2010

HRV devices reduce respiratory symptoms in children: Study

Houses today are so well sealed that they can trap humidity and pollutants indoors as a result of insufficient ventilation. Recently, a team of Canadian scientists led by Dr. Tom Kovesi, a pediatric respirologist at the Children's Hospital of Eastern Ontario in Ottawa, Canada, performed a randomized double-blind, placebo controlled trial to determine whether use of heat recovery ventilators would increase home ventilation and therefore reduce the risk of lower respiratory tract illness in young children.

7 Apr 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

Genta reports net loss of $11.7M for fourth-quarter 2009

Genta Incorporated today reported results for the quarter and year ended December 31, 2009. The Company also provided an overview of recent corporate highlights and anticipated milestones.

29 Mar 2010

Lung transplant patients may one day benefit from synthetic peptide, researchers report

Lung transplant patients may one day benefit from a synthetic peptide that mimics the body's natural ability to reduce excess fluid accumulation, Medical College of Georgia researchers report.

26 Mar 2010

DARA BioSciences announces the initiation of Phase I clinical study for DB959

DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.

26 Mar 2010

Aradigm reports net loss of $3.4M for fourth-quarter 2009

Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2009.

23 Mar 2010

Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.

19 Mar 2010

PhRMA President honors Ron and Raychel Bartek for driving awareness of Friedreich's ataxia

Pharmaceutical Research and Manufacturers of America President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.

19 Mar 2010

Call for European Cystic Fibrosis healthcare gap to be closed

A healthcare gap amounting to a ‘death sentence’ for Cystic Fibrosis (CF) children born in Eastern Europe must be closed say researchers from the EuroCareCF Coordination Action for Cystic Fibrosis.

18 Mar 2010

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics Inc., a U.S. based genetic testing company, announced the immediate availability of its personal Genetic Health Report. This customized and innovative personal genetic health report contains information on more than 70 health conditions, including pharmacogenetics (prescription medication response), propensity for complex disease, and carrier status (pre-pregnancy health).

17 Mar 2010

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Vertex Pharmaceuticals Incorporated today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010.

17 Mar 2010

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Inspire Pharmaceuticals, Inc. announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue pursuing a potential indication for treatment of anterior and posterior forms of blepharitis.

15 Mar 2010

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Exclusive licensing practices slows innovation in gene testing market

FDA approves J&JPRD's PANCREAZE NDA

Stem cell scientists receive stimulus grants to study lung and blood disorders

Pancreaze Delayed Release Capsules receive FDA approval

Latest advancement in the development of lab tests for bipolar disorder

Tβ4 therapy for ocular disorders closer to reality

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

HRV devices reduce respiratory symptoms in children: Study

PhRMA report: 234 medicines in development for special health care needs of children

Genta reports net loss of $11.7M for fourth-quarter 2009

Lung transplant patients may one day benefit from synthetic peptide, researchers report

DARA BioSciences announces the initiation of Phase I clinical study for DB959

Aradigm reports net loss of $3.4M for fourth-quarter 2009

Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients

PhRMA President honors Ron and Raychel Bartek for driving awareness of Friedreich's ataxia

Call for European Cystic Fibrosis healthcare gap to be closed

Pathway Genomics' personal Genetic Health Report now available

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Innovation in neuroscience drug discovery - eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Innovation in neuroscience drug discovery - eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in